Journal: Cell Death Discovery

Article Title: The palladacycle complex AJ-5 induces apoptotic cell death while reducing autophagic flux in rhabdomyosarcoma cells

doi: 10.1038/s41420-019-0139-9

Figure Lengend Snippet: a MTT cell viability assays of aRMS cell lines, RH30 and AX-OH-1, and eRMS cell lines, RD and FL-OH-1, treated with a range of AJ-5 concentrations (0.1–1.0 µM) or vehicle for 48 h. Graphs show mean cell viability as a percentage of vehicle control ± SEM for each concentration of AJ-5 determined from three independent experiments performed in quadruplicate. A curve was fitted to determine the IC 50 concentration of AJ-5 for each cell line. b Representative light microscopy images (×200; EVOS XL AMEX1000 Core Imaging System) of aRMS and eRMS cell lines treated with their respective IC 50 concentrations of AJ-5 or vehicle for 24 and 48 h. c MTT cell viability assays of non-malignant human fibroblast cell lines, FG0 and DMB, mouse myoblast cell line, C2C12, and mesenchymal stem cell line, A10021501, treated with AJ-5 and IC 50 concentrations determined as described in a above. Selectivity indices (SIs) were determined for each RMS cell line by dividing the IC 50 of each non-malignant cell line by the IC 50 of each RMS cell line

Article Snippet: RD human eRMS cells (ATCC ® CCL-136 TM ), FG0 and DMB human skin fibroblasts (kindly provided by Associate Professor Denver Hendricks, University of Cape Town), mouse myoblast cells (ATCC ® CRL-1772 TM ), human mesenchymal stem cells A10021501 (kindly provided by Professor Michael Pepper, University of Pretoria and confirmed to meet the criteria to be defined as mesenchymal stem cells as set out by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy ), HT1080 human fibrosarcoma cells (ATCC ® CCL-120 TM ), SW1353 human chondrosarcoma cells (ATCC ® HTB-94 TM ), SW982 human synovial sarcoma cells (ATCC ® HTB-93 TM ), SW872 human liposarcoma (ATCC ® HTB-92 TM ) and MG-63 human osteosarcoma cells (kindly provided by Associate Professor Philippa Hulley, University of Oxford) were cultured in Dulbecco’s modified Eagle’s medium (Sigma Aldrich).

Techniques: Control, Concentration Assay, Light Microscopy, Imaging

Journal: Stem Cells Translational Medicine

Article Title: Mesenchymal Stromal Cells Anno 2019: Dawn of the Therapeutic Era? Concise Review

doi: 10.1002/sctm.19-0073

Figure Lengend Snippet: Distribution of preclinical mesenchymal stem calls (MSC) studies in inflammatory diseases with a focus on sepsis, acute lung injury, acute respiratory distress syndrome, arthritis, and colitis, based on MSC origin (autologous, allogeneic or xenogeneic) with corresponding therapeutic outcome

Article Snippet: The TiGenix‐sponsored randomized, double‐blind, parallel‐group, placebo‐controlled phase III clinical trial, NCT01541579, reported statistically significant improvement of intralesional administration of 120 million allogeneic expanded adipose mesenchymal stem cells (darvadstrocel, formerly Cx601) over control in the treatment of complex perianal fistulas in Crohn's disease patients .

Techniques: